SCHEDULE: Insider Sells Marker Therapeutics Shares
Beneficial Ownership Change
John R. Wilson's trust has reduced its beneficial ownership in Marker Therapeutics, Inc. to below 5% through a series of open market sales.
Summary
- John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017, has decreased its beneficial ownership in Marker Therapeutics, Inc.
- The trust now beneficially owns 641,801 shares of Common Stock, representing 4.96% of the Issuer's outstanding shares.
- This reduction resulted from the sale of 139,399 shares through multiple open market transactions between August 6, 2025, and August 19, 2025.
- Sale prices for these transactions ranged from $1.1422 to $1.2898 per share.
- The percentage of ownership is calculated based on 12,938,910 shares outstanding as of August 4, 2025, as reported in the Issuer's Form 10-Q filed on August 14, 2025.
Sentiment
Score: 3
Explanation: The filing reports significant insider selling by a former director's trust, reducing their stake below 5%. While the specific reasons for the sales are not disclosed, such activity by a knowledgeable insider is generally viewed as a negative indicator, suggesting potential concerns about future performance or valuation.
Negatives
- A significant insider, John R. Wilson's trust, has reduced its beneficial ownership below the 5% threshold.
- The sale of 139,399 shares by a former director's trust could signal a lack of confidence or a need for liquidity, which may be viewed negatively by the market.
Future Outlook
No forward-looking statements or guidance are provided in this filing.
Industry Context
This filing is a specific disclosure of an insider's change in beneficial ownership and does not provide broader industry context or trends.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | John R. Wilson | N/A | 01/24/2025 | Resignation from the Board of Directors |
Stakeholder Impact
- Shareholders may perceive the significant insider selling by a former director's trust as a negative signal, potentially impacting investor confidence and the company's stock price.
Key Dates
| Date | Description |
|---|---|
| 08/03/2017 | Date of John R. Wilson Revocable Trust U/A DTD |
| 01/24/2025 | John R. Wilson resigned from the Issuer's Board of Directors |
| 08/04/2025 | Date for outstanding shares calculation (12,938,910 shares) |
| 08/06/2025 | Start date of stock sales by the Reporting Person |
| 08/14/2025 | Issuer's Report on Form 10-Q filed with the SEC |
| 08/19/2025 | End date of stock sales by the Reporting Person and date of event requiring filing |
| 08/20/2025 | Date of signature for the Schedule 13D/A filing |
Recommendation
holdThe significant insider selling by a former director's trust, reducing their stake below 5%, presents a negative signal. While the specific reasons for the sales are not disclosed, this action by a knowledgeable party warrants caution. Investors should hold their positions and closely monitor future company performance, additional insider activity, and broader market conditions before making further investment decisions.
Keywords
Marker Therapeutics, John R. Wilson, Schedule 13D, insider selling, beneficial ownership, common stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.